ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2020
Cancer immunotherapy-related adverse events: causes and challenges.
Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07581080 (Biofield Therapy for the Support of Immunotherapy-related Symptoms Among Adult Cancer Patients - A Pilot Study), which is not on this map. Cited by 20 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Biofield Therapy for the Support of Immunotherapy-related Symptoms Among Adult Cancer Patients - A Pilot Study
Who cites it
20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- A systematic review of gastritis as an immune-related adverse event in clinical interventions.Human vaccines & immunotherapeutics · 2024Pooled it
- Adverse events of neoadjuvant combination immunotherapy for resectable cancer patients: a systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Safety of Neoadjuvant Immunotherapy in Resectable Cancers: A Meta-Analysis.Frontiers in immunology · 2022Pooled it
- Preexisting autoimmune disease is a risk factor for immune-related adverse events: a meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Pooled it
- Defining the tumor microenvironment of non-small cell lung cancer.Immunology and cell biology · 2026Review
- Role of innate immunity in the development of cancer immunotherapy immune-mediated adverse events.Frontiers in immunology · 2026Review
- Non-pharmacological Supportive Care Interventions during Immunotherapy for People with Cancer: A Systematic Scoping Review and Future Directions.Current oncology reports · 2025Article
- CD155-TIGIT Axis as a Therapeutic Target for Cancer Immunotherapy.Current medicinal chemistry · 2024Review
- In silico evolution of autoinhibitory domains for a PD-L1 antagonist using deep learning models.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- The opportunities and challenges of perioperative therapy of localized non-small cell lung cancer-thoughts from the KEYNOTE-671 trial.Translational lung cancer research · 2023Article
- The need for ambulatory emergency oncology: exemplified by the management of immune checkpoint inhibitor toxicity.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- The safety profile of nivolumab plus ipilimumab combination therapy in Japanese patients with renal cell carcinoma: results from post-marketing surveillance.Japanese journal of clinical oncology · 2023Article
- First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.Cancer immunology, immunotherapy : CII · 2023Article
- Article
- Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy.Journal of cancer research and clinical oncology · 2023Article
- Application of injectable hydrogels in cancer immunotherapy.Frontiers in bioengineering and biotechnology · 2023Review
- Dendritic cells transfected with a polyepitope DNA construct stimulate an antitumor cytotoxic response in various tumors.Molecular and clinical oncology · 2022Article
- Checkpoint Inhibitors and Induction of Celiac Disease-like Condition.Biomedicines · 2022Review
- Palliative care physicians' recognition of patients after immune checkpoint inhibitors and immune-related adverse events.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the success and ongoing promise of monoclonal antibody-targeted immune checkpoint inhibitor immunotherapy of advanced malignancies, in particular, antibodies directed against CTLA-4 and PD-1/PD-L1, the development of immune-related adverse events (irAEs) remains a constraint of this type of therapy. Although rarely fatal, the occurrence of irAEs may necessitate discontinuation of immunotherapy, as well as administration of corticosteroids or other immunosuppressive therapies that may not only compromise efficacy but also predispose for development of opportunistic infection. Clearly, retention of efficacy of immune checkpoint-targeted therapies with concurrent attenuation of immune-mediated toxicity represents a formidable challenge. In this context, the current brief review examines mechanistic relationships between these events, as well as recent insights into immunopathogenesis, and strategies which may contribute to resolving this issue. These sections are preceded by brief overviews of the discovery and functions of CTLA-4 and PD-1, as well as the chronology of the development of immunotherapeutic monoclonal antibodies which target these immune checkpoint inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.